Antibodies against flagellin and uses thereof
AssigneesInotek Pharmaceuticals Corporation, Yeda Research and Development Co. Ltd.
InventorsNurit Rachamim, Andrew L. Salzman, Kanneganti Murthy
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.
Claims15
An isolated monoclonal antibody that binds to flagellin comprising a heavy and light chain variable region comprising the amino acid sequences set forth in SEQ ID NOs:2 and 4, respectively.
An isolated monoclonal antibody that binds to flagellin and comprises heavy and light chain variable CDR1, CDR2 and CDR3 regions, wherein the heavy chain variable CDR1 comprises SEQ ID NO:6;
- the heavy chain variable CDR2 comprises SEQ ID NO:8;
- the heavy chain variable CDR3 comprises SEQ ID NO:10;
- the light chain variable CDR1 comprises SEQ ID NO:12;
- the light chain variable CDR2 comprises SEQ ID NO:
- 14;
- and
- the light chain variable CDR3 comprises SEQ ID NO:
- 16.
Dependencies are inferred from the claim text.